Zafgen, Inc. (NASDAQ:ZFGN) Director Frances K. Heller acquired 10,000 shares of Zafgen stock in a transaction dated Friday, October 13th. The stock was bought at an average price of $3.90 per share, for a total transaction of $39,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Zafgen, Inc. (NASDAQ:ZFGN) traded down 8.38% during mid-day trading on Tuesday, reaching $3.61. The company’s stock had a trading volume of 150,144 shares. The stock’s 50 day moving average price is $3.49 and its 200 day moving average price is $3.86. Zafgen, Inc. has a 1-year low of $2.89 and a 1-year high of $5.46. The stock’s market capitalization is $99.21 million.

Zafgen (NASDAQ:ZFGN) last announced its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.49) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.52) by $0.03. During the same quarter in the previous year, the firm earned ($0.55) EPS. Analysts expect that Zafgen, Inc. will post ($2.23) EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This news story was posted by American Banking News and is the sole property of of American Banking News. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright laws. The correct version of this news story can be read at https://www.americanbankingnews.com/2017/10/17/zafgen-inc-zfgn-director-acquires-39000-00-in-stock.html.

Several analysts have recently issued reports on the company. ValuEngine upgraded Zafgen from a “strong sell” rating to a “sell” rating in a research note on Monday. Zacks Investment Research cut Zafgen from a “buy” rating to a “hold” rating in a research note on Thursday, October 12th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and one has assigned a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average price target of $6.38.

A number of large investors have recently bought and sold shares of ZFGN. Algert Global LLC purchased a new position in Zafgen in the 2nd quarter valued at about $123,000. Parametric Portfolio Associates LLC boosted its position in Zafgen by 55.8% in the 1st quarter. Parametric Portfolio Associates LLC now owns 28,832 shares of the biopharmaceutical company’s stock valued at $134,000 after buying an additional 10,327 shares during the last quarter. Wells Fargo & Company MN boosted its position in Zafgen by 1,290.3% in the 1st quarter. Wells Fargo & Company MN now owns 43,531 shares of the biopharmaceutical company’s stock valued at $203,000 after buying an additional 40,400 shares during the last quarter. GSA Capital Partners LLP purchased a new position in Zafgen in the 2nd quarter valued at about $259,000. Finally, LMR Partners LLP purchased a new position in Zafgen in the 2nd quarter valued at about $299,000. 48.52% of the stock is owned by institutional investors.

About Zafgen

Zafgen, Inc is a biopharmaceutical company. The Company is focused on improving the health and well-being of patients affected by obesity and complex metabolic disorders. The Company’s lead product candidate, Beloranib, is a twice-weekly subcutaneous injection being developed for the treatment of multiple indications, including severe obesity in rare diseases, such as Prader-Willi syndrome (PWS) and hypothalamic injury-associated obesity (HIAO), including craniopharyngioma-associated obesity.

Receive News & Ratings for Zafgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zafgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.